Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Michael Grissinger is Director at Aprea Therapeutics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Aug 7, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
LipocineLPCN
Aug 3, 20262,000disclosed Aug 7
DetailsOfficial recordAprea TherapeuticsAPRE
2 disclosures · Jun 2026
Jun 16, 20263,135disclosed Jun 17
DetailsOfficial recordJun 16, 202613Kdisclosed Jun 17
DetailsOfficial recordOn the latest SEC Form 4, dated Jun 16, 2026, Michael Grissinger reported holding 6,024 shares of Aprea Therapeutics (APRE). At the last close of $0 on Nov 13, 2026, that is about $2.5K. This is the stake disclosed in filings, not a net worth.
As of the latest filing on , Michael Grissinger reported holding 6,024 shares of Aprea Therapeutics (APRE), worth about $2.5K at the last close of $0 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Aprea Therapeutics APRE | 6,024 | 6,024 direct | $0 | $2.5K | Jun 16, 2026 |
Is this Michael Grissinger’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
